Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 19 | 2020 | 3680 | 1.500 |
Why?
|
| Delirium | 9 | 2018 | 1610 | 1.280 |
Why?
|
| Sleep Deprivation | 6 | 2020 | 832 | 1.250 |
Why?
|
| Critical Care | 11 | 2019 | 2647 | 1.030 |
Why?
|
| Epoprostenol | 2 | 2015 | 254 | 0.920 |
Why?
|
| Critical Illness | 11 | 2020 | 2670 | 0.910 |
Why?
|
| Tranexamic Acid | 1 | 2023 | 146 | 0.810 |
Why?
|
| Antifibrinolytic Agents | 2 | 2023 | 254 | 0.800 |
Why?
|
| Ear Protective Devices | 1 | 2016 | 9 | 0.560 |
Why?
|
| Analgesics | 2 | 2016 | 1040 | 0.550 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2016 | 130 | 0.530 |
Why?
|
| Hypnotics and Sedatives | 2 | 2016 | 1162 | 0.510 |
Why?
|
| Respiratory Insufficiency | 2 | 2015 | 1199 | 0.510 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2017 | 1354 | 0.450 |
Why?
|
| Respiratory Muscles | 1 | 2013 | 139 | 0.430 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 738 | 0.430 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 783 | 0.420 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2015 | 271 | 0.400 |
Why?
|
| Administration, Inhalation | 3 | 2023 | 1105 | 0.390 |
Why?
|
| Checklist | 1 | 2018 | 833 | 0.380 |
Why?
|
| Deep Sedation | 4 | 2018 | 121 | 0.370 |
Why?
|
| Tetrazoles | 1 | 2015 | 835 | 0.360 |
Why?
|
| Respiration Disorders | 1 | 2013 | 371 | 0.350 |
Why?
|
| Bronchodilator Agents | 1 | 2013 | 502 | 0.350 |
Why?
|
| Psychomotor Agitation | 4 | 2018 | 293 | 0.340 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 845 | 0.330 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2013 | 518 | 0.310 |
Why?
|
| Tracheostomy | 1 | 2011 | 401 | 0.300 |
Why?
|
| Fatigue | 1 | 2015 | 1531 | 0.300 |
Why?
|
| Conscious Sedation | 4 | 2018 | 528 | 0.290 |
Why?
|
| Radiography | 1 | 2018 | 7023 | 0.290 |
Why?
|
| Quality Improvement | 2 | 2019 | 3749 | 0.280 |
Why?
|
| Sleep | 4 | 2023 | 4623 | 0.270 |
Why?
|
| Restraint, Physical | 4 | 2018 | 193 | 0.250 |
Why?
|
| Survivors | 4 | 2019 | 2291 | 0.250 |
Why?
|
| Peer Group | 3 | 2019 | 635 | 0.240 |
Why?
|
| Sleep Stages | 1 | 2008 | 686 | 0.240 |
Why?
|
| Nitric Oxide | 1 | 2013 | 2132 | 0.240 |
Why?
|
| Pyridines | 1 | 2015 | 2825 | 0.230 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 2047 | 0.230 |
Why?
|
| Surgical Procedures, Operative | 1 | 2015 | 1876 | 0.220 |
Why?
|
| Hemoptysis | 1 | 2023 | 155 | 0.210 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2014 | 194 | 0.210 |
Why?
|
| Propofol | 2 | 2017 | 629 | 0.180 |
Why?
|
| Lung Diseases | 3 | 2021 | 1887 | 0.160 |
Why?
|
| Hermanski-Pudlak Syndrome | 1 | 2018 | 22 | 0.160 |
Why?
|
| Self-Help Groups | 1 | 2019 | 190 | 0.160 |
Why?
|
| Social Support | 2 | 2019 | 2118 | 0.150 |
Why?
|
| Oxygenators | 1 | 2017 | 34 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2019 | 392 | 0.150 |
Why?
|
| Respiration, Artificial | 3 | 2015 | 2569 | 0.140 |
Why?
|
| Subacute Care | 1 | 2019 | 168 | 0.140 |
Why?
|
| Humans | 40 | 2023 | 744376 | 0.130 |
Why?
|
| Positive-Pressure Respiration | 2 | 2010 | 633 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2014 | 15295 | 0.130 |
Why?
|
| Midazolam | 1 | 2016 | 270 | 0.120 |
Why?
|
| Noise | 1 | 2016 | 279 | 0.120 |
Why?
|
| Fentanyl | 1 | 2016 | 409 | 0.110 |
Why?
|
| Bronchi | 2 | 2019 | 840 | 0.110 |
Why?
|
| Biomedical Research | 3 | 2018 | 3309 | 0.110 |
Why?
|
| Pain | 2 | 2018 | 4987 | 0.110 |
Why?
|
| Busulfan | 1 | 2014 | 263 | 0.110 |
Why?
|
| Length of Stay | 2 | 2016 | 6311 | 0.110 |
Why?
|
| Male | 20 | 2023 | 350118 | 0.110 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1993 | 293 | 0.110 |
Why?
|
| APACHE | 1 | 2013 | 277 | 0.110 |
Why?
|
| Standard of Care | 2 | 2019 | 564 | 0.110 |
Why?
|
| Dexmedetomidine | 1 | 2016 | 315 | 0.100 |
Why?
|
| Female | 20 | 2023 | 380200 | 0.100 |
Why?
|
| Adult | 18 | 2023 | 214056 | 0.100 |
Why?
|
| Middle Aged | 18 | 2019 | 213388 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 1049 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 976 | 0.100 |
Why?
|
| Manometry | 1 | 2013 | 445 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2023 | 3743 | 0.100 |
Why?
|
| Aged | 10 | 2023 | 163284 | 0.090 |
Why?
|
| Benzodiazepines | 1 | 2016 | 1101 | 0.090 |
Why?
|
| Shock, Cardiogenic | 1 | 2015 | 688 | 0.090 |
Why?
|
| Lung Transplantation | 1 | 2018 | 1155 | 0.090 |
Why?
|
| Patients | 1 | 2016 | 900 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2014 | 5445 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 1617 | 0.080 |
Why?
|
| Equipment and Supplies | 1 | 2011 | 281 | 0.080 |
Why?
|
| Electromyography | 1 | 2013 | 1379 | 0.080 |
Why?
|
| Syndrome | 2 | 2016 | 3252 | 0.080 |
Why?
|
| High-Frequency Ventilation | 1 | 1988 | 87 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2018 | 2265 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2023 | 77459 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 2242 | 0.070 |
Why?
|
| Esophagus | 1 | 2013 | 1019 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 1599 | 0.070 |
Why?
|
| Bronchoscopy | 2 | 2019 | 862 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 3395 | 0.070 |
Why?
|
| Speech | 1 | 2011 | 541 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 5390 | 0.070 |
Why?
|
| Glycoproteins | 1 | 1993 | 2266 | 0.070 |
Why?
|
| Dyspnea | 1 | 2013 | 1303 | 0.060 |
Why?
|
| Restless Legs Syndrome | 1 | 2008 | 228 | 0.060 |
Why?
|
| Catecholamines | 1 | 2006 | 387 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 3086 | 0.060 |
Why?
|
| Oxygen | 3 | 2010 | 4189 | 0.060 |
Why?
|
| Endothelium, Vascular | 2 | 1993 | 4458 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 1868 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2016 | 3461 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 2624 | 0.060 |
Why?
|
| Polysomnography | 2 | 2023 | 1776 | 0.060 |
Why?
|
| Sleep, REM | 1 | 2006 | 595 | 0.050 |
Why?
|
| Hormones | 1 | 2006 | 889 | 0.050 |
Why?
|
| Comorbidity | 2 | 2014 | 10388 | 0.050 |
Why?
|
| Thrombosis | 1 | 2016 | 2968 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 2958 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7281 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2023 | 40558 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2016 | 4244 | 0.050 |
Why?
|
| Vital Capacity | 2 | 2014 | 925 | 0.050 |
Why?
|
| Qualitative Research | 2 | 2019 | 2682 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 3677 | 0.050 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2008 | 944 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2015 | 63115 | 0.040 |
Why?
|
| Forced Expiratory Volume | 2 | 2014 | 1745 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2017 | 53291 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 2765 | 0.040 |
Why?
|
| Disease Progression | 1 | 2013 | 13285 | 0.030 |
Why?
|
| Feedback | 1 | 2019 | 795 | 0.030 |
Why?
|
| Models, Economic | 1 | 2019 | 712 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 13104 | 0.030 |
Why?
|
| Risk Factors | 4 | 2020 | 72295 | 0.030 |
Why?
|
| Time Factors | 1 | 2015 | 40077 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2016 | 426 | 0.030 |
Why?
|
| Cost Savings | 1 | 2019 | 925 | 0.030 |
Why?
|
| Pulmonary Fibrosis | 1 | 2018 | 530 | 0.030 |
Why?
|
| Bronchography | 1 | 2012 | 74 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 1683 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2014 | 492 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2019 | 2539 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1405 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2012 | 132 | 0.020 |
Why?
|
| Actigraphy | 1 | 2015 | 488 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 520 | 0.020 |
Why?
|
| Cattle | 2 | 1993 | 3922 | 0.020 |
Why?
|
| Surface Properties | 1 | 1993 | 1184 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 1993 | 822 | 0.020 |
Why?
|
| Family | 1 | 2019 | 3147 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6755 | 0.020 |
Why?
|
| Hospitalization | 1 | 2006 | 10259 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 1993 | 2700 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 35424 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2019 | 3318 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2021 | 7730 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2019 | 6194 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2014 | 21747 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 2575 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 3842 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 2618 | 0.020 |
Why?
|
| Young Adult | 3 | 2016 | 56434 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1988 | 1150 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14723 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1988 | 2556 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20130 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 9445 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5135 | 0.010 |
Why?
|
| United States | 2 | 2023 | 69869 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 4153 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 57776 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 12244 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39052 | 0.010 |
Why?
|
| Prevalence | 1 | 2014 | 15221 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 10183 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 15078 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2005 | 5316 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1993 | 675 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1993 | 2008 | 0.010 |
Why?
|
| Animals | 2 | 1993 | 168770 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1993 | 19233 | 0.000 |
Why?
|
| Rats | 1 | 1993 | 24252 | 0.000 |
Why?
|
Concepts
(175)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(33)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_